Cardiovascular effects of omega-3 fatty acids: Hope or hype?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jo, Sang-Ho | - |
dc.contributor.author | Han, Seung Hwan | - |
dc.contributor.author | Kim, Sang-Hyun | - |
dc.contributor.author | Eckel, R.H. | - |
dc.contributor.author | Koh, Kwang Kon | - |
dc.date.available | 2021-04-30T00:35:37Z | - |
dc.date.created | 2021-03-15 | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 0021-9150 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/80875 | - |
dc.description.abstract | Omega-3 fatty acids have emerged as a new option for controlling the residual risk for cardiovascular disease (CVD) in the statin era after a clinical trial (REDUCE-IT) reported positive results with icosapent ethyl (IPE) in patients receiving maximally tolerated statin therapy. However, another trial which used high dose eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) combination (STRENGTH) has failed. Together, these results raise clinically important questions. Are effects of omega-3 fatty acids neutral or beneficial in patients on statin therapy, or perhaps even harmful? The current contradictory results could be attributed to different types of omega-3 fatty acids (only EPA or combination of EPA + DHA), doses (higher vs. lower dose) of omega-3 fatty acids or different comparators (corn oil or mineral oil), as well as the underlying severity of the CVD risk or use of statins. Together with these issues, we will discuss different biological and clinical effects of various types of omega-3 fatty acids and then interpret different results of past and current clinical studies and propose practical suggestions, which could be applied in patient management. © 2021 | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Elsevier Ireland Ltd | - |
dc.relation.isPartOf | Atherosclerosis | - |
dc.title | Cardiovascular effects of omega-3 fatty acids: Hope or hype? | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000636608800003 | - |
dc.identifier.doi | 10.1016/j.atherosclerosis.2021.02.014 | - |
dc.identifier.bibliographicCitation | Atherosclerosis, v.322, pp.15 - 23 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85102022818 | - |
dc.citation.endPage | 23 | - |
dc.citation.startPage | 15 | - |
dc.citation.title | Atherosclerosis | - |
dc.citation.volume | 322 | - |
dc.contributor.affiliatedAuthor | Han, Seung Hwan | - |
dc.contributor.affiliatedAuthor | Koh, Kwang Kon | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Atherosclerosis | - |
dc.subject.keywordAuthor | Omega-3 fatty acids | - |
dc.subject.keywordAuthor | Residual cardiovascular risk | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.